I6T-MC-AMAX; A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn’s Disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502841-91-00

Acronym

I6T-MC-AMAX

Enrollment

338

Registered

2024-06-19

Start date

2020-08-12

Completion date

Unknown

Last updated

2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn’s Disease

Brief summary

Percentage of Participants Achieving Endoscopic Response (Endoscopic response based on Simple Endoscopic Score for Crohn’s Disease (SES-CD) total score) [Time Frame: Week 52], Percentage of Participants Achieving Clinical Remission (Clinical remission based on CDAI) [Time Frame: Week 52]

Interventions

DRUGMirikizumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of Participants Achieving Endoscopic Response (Endoscopic response based on Simple Endoscopic Score for Crohn’s Disease (SES-CD) total score) [Time Frame: Week 52], Percentage of Participants Achieving Clinical Remission (Clinical remission based on CDAI) [Time Frame: Week 52]	—

Countries

Austria, Belgium, Croatia, Czechia, France, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, Poland, Romania, Slovakia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026